In the Company entered into an agreement with the Moores Cancer Center at the University of California San Diego (UCSD) to provide pharmacology lab services to the Company. Dr. Stephen Howell is the Acting Chief Medical Officer of Aptose and is also a Professor of Medicine at UCSD and will be overseeing the laboratory work. The research services will be provided from to and will be billed monthly for services rendered.

 

The total amount for services provided under the agreement is to exceed thousand. In the Company entered into another agreement with UCSD for an additional month period for services up to These transactions are in the normal course of business and are measured at the amount of consideration established and agreed to by the related parties.

 

During year ended the Company recorded thousand ( – thousand) in research and development expenses related to the agreement.

 

Compensation of key management personnel:

 

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the Company’s activities as a whole. The Company has determined that key management personnel consist of the members of the Board of Directors along with the officers of the Company. For the years ended and the officers were the Chairman, President and Chief Executive Officer, the Senior Vice President and Chief Financial Officer as well as the Senior Vice President and the former Chief Business Officer.

 

Officer compensation:

 

		Year ended December 31, 2017				Year ended December 31, 2016				Year ended December 31, 2015
						As recast (note 3(b))				As recast (note 3(b))
Salaries and short-term employee benefits		$	1,605			$	1,543			$	1,457
Stock-based compensation			371				1,191				1,871
		$	1,976			$	2,734			$	3,328

 

Director compensation:

 

		Year ended December 31, 2017				Year ended December 31, 2016				Year ended December 31, 2015
						As recast (note 3(b))				As recast (note 3(b))
Directors’ fees		$	240			$	240			$	239
Stock-based compensation			128				157				273
		$	368			$	397			$	512

 

The amounts disclosed in the table above have been recognized as an expense during the reporting period related to key management personnel. Included in accounts payable and accrued liabilities, is thousand ( - thousand, – thousand) owing to directors and officers of the Company relating to unpaid compensation and directors’ fee.